These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8463136)

  • 1. Comparative studies on the metabolism of new fluorinated pyrimidine drugs in the liver by in vivo 19F magnetic resonance spectroscopic observation.
    Harada M; Nishitani H; Koga K; Miura I; Kimura A
    Jpn J Cancer Res; 1993 Feb; 84(2):197-202. PubMed ID: 8463136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
    Tatsumi K; Yamauchi T; Kiyono K; Kishi K; Yanagihara Y; Imaoka T; Kawaguchi T; Kubo M
    J Biochem; 1993 Dec; 114(6):912-8. PubMed ID: 8138551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
    Fujii S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2244-50. PubMed ID: 2955745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of tegafur in rat liver observed by in vivo 19F magnetic resonance spectroscopy and chromatography.
    Harada M; Nishitani H; Koga K; Miura I; Umeno Y
    Jpn J Cancer Res; 1992 Apr; 83(4):387-91. PubMed ID: 1506273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy].
    Shirasaka T; Fujii S
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy.
    Adams ER; Leffert JJ; Craig DJ; Spector T; Pizzorno G
    Cancer Res; 1999 Jan; 59(1):122-7. PubMed ID: 9892196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.
    Tatsumi K; Fukushima M; Shirasaka T; Fujii S
    Jpn J Cancer Res; 1987 Jul; 78(7):748-55. PubMed ID: 3114201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymes of uracil catabolism in normal and neoplastic human tissues.
    Naguib FN; el Kouni MH; Cha S
    Cancer Res; 1985 Nov; 45(11 Pt 1):5405-12. PubMed ID: 3931905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
    Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
    Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase.
    Tuchman M; Ramnaraine ML; O'Dea RF
    Cancer Res; 1985 Nov; 45(11 Pt 1):5553-6. PubMed ID: 4053028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo 19F NMR comparative study of 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil (FT) and an FT-uracil coadministration system in mouse tumors.
    Kanazawa Y; Kurogi S; Shinohara S; Noda Y; Masuda K
    Chem Pharm Bull (Tokyo); 1994 Apr; 42(4):774-8. PubMed ID: 8020119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors].
    Harada M; Nishitani H; Shirahama T; Koga K; Miura I
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
    Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T
    Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral DPD-inhibitory fluoropyrimidine drugs.
    Diasio RB
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metabolic characteristics and antitumor activity of BOF-A2, a new 5-fluorouracil derivative].
    Shirasaka T; Fukushima M; Shimamoto Y; Kimura Y; Ohshimo H; Imaoka T; Kimura A; Utsunomiya T; Fujii S
    Gan To Kagaku Ryoho; 1990 May; 17(5):1051-8. PubMed ID: 2334171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dose, administration time and route and hepatic function-dependent metabolism of 5-FU in mice].
    Okamoto M; Takao A; Fujita H
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3483-90. PubMed ID: 3789759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent (drug combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats.
    Yoshisue K; Masuda H; Matsushima E; Ikeda K; Nagayama S; Kawaguchi Y
    Drug Metab Dispos; 2000 Oct; 28(10):1162-7. PubMed ID: 10997934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
    Suenaga M
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3313-8. PubMed ID: 2825604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism.
    Davis LE; Lenkinski RE; Shinkwin MA; Kressel HY; Daly JM
    Cancer; 1993 Dec; 72(12):3715-22. PubMed ID: 8252488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay.
    Traut TW; Loechel S
    Biochemistry; 1984 May; 23(11):2533-9. PubMed ID: 6433973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.